Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 35

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

HSV-2 vaccine: Current state and insights into development of a vaccine that targets genital mucosal protection

Roth, Kristy, Ferreira, Victor H., Kaushic, Charu · 2013 · Microbial Pathogenesis

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.micpath.2012.11.001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 144

  1. Looker, 2008, An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection, Bull World Health Organ, 86, 805, 10.2471/BLT.07.046128 · DOI · Paper page
  2. Xu, 2006, Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States, JAMA, 296, 964, 10.1001/jama.296.8.964 · DOI · Paper page
  3. Johnston, 2011, HSV-2: in pursuit of a vaccine, J Clin Invest, 121, 4600, 10.1172/JCI57148 · DOI
  4. Szucs, 2001, The estimated economic burden of genital herpes in the United States. An analysis using two costing approaches, BMC Infect Dis, 1, 5, 10.1186/1471-2334-1-5 · DOI
  5. Tao, 2000, Medical care expenditures for genital herpes in the United States, Sex Transm Dis, 27, 32, 10.1097/00007435-200001000-00007 · DOI
  6. Fisman, 2003, Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2, Sex Transm Infect, 79, 45, 10.1136/sti.79.1.45 · DOI
  7. Kimberlin, 2004, Clinical practice. Genital herpes, N Engl J Med, 350, 1970, 10.1056/NEJMcp023065 · DOI · Paper page
  8. Cunningham, 2006, The cycle of human herpes simplex virus infection: virus transport and immune control, J Infect Dis, 194, S11, 10.1086/505359 · DOI · Paper page
  9. Brown, 1997, The acquisition of herpes simplex virus during pregnancy, N Engl J Med, 337, 509, 10.1056/NEJM199708213370801 · DOI · Paper page
  10. Brown, 2003, Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant, JAMA, 289, 203, 10.1001/jama.289.2.203 · DOI · Paper page
  11. Dinh, 2008, Assessing neonatal herpes reporting in the United States, 2000–2005, Sex Transm Dis, 35, 19, 10.1097/OLQ.0b013e318162c4c6 · DOI
  12. Freeman, 2006, Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies, Aids, 20, 73, 10.1097/01.aids.0000198081.09337.a7 · DOI · Paper page
  13. Celum, 2004, The interaction between herpes simplex virus and human immunodeficiency virus, Herpes, 11, 36A
  14. Mole, 1997, The impact of active herpes simplex virus infection on human immunodeficiency virus load, J Infect Dis, 176, 766, 10.1086/517297 · DOI · Paper page
  15. Zhu, 2009, Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition, Nat Med, 15, 886, 10.1038/nm.2006 · DOI · Paper page
  16. Ferreira, 2011, Endometrial epithelial cell responses to coinfecting viral and bacterial pathogens in the genital tract can activate the HIV-1 LTR in an NF{kappa}B-and AP-1-dependent manner, J Infect Dis, 204, 299, 10.1093/infdis/jir260 · DOI
  17. Xu, 2002, Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994, J Infect Dis, 185, 1019, 10.1086/340041 · DOI · Paper page
  18. Wald, 2000, Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons, N Engl J Med, 342, 844, 10.1056/NEJM200003233421203 · DOI · Paper page
  19. Mark, 2008, Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults, J Infect Dis, 198, 1141, 10.1086/591913 · DOI · Paper page
  20. Crespi, 2007, Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling, Sex Transm Infect, 83, 359, 10.1136/sti.2006.022020 · doi:10.1136/sti.2006.022020
  21. Wald, 1997, Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment, J Clin Invest, 99, 1092, 10.1172/JCI119237 · DOI · Paper page
  22. Tronstein, 2011, Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection, JAMA, 305, 1441, 10.1001/jama.2011.420 · DOI · Paper page
  23. Mertz, 1992, Risk factors for the sexual transmission of genital herpes, Ann Intern Med, 116, 197, 10.7326/0003-4819-116-3-197 · DOI · Paper page
  24. Wald, 2006, Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition, J Infect Dis, 194, 42, 10.1086/504717 · DOI
  25. Posavad, 2010, Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons, J Immunol, 184, 3250, 10.4049/jimmunol.0900722 · doi:10.4049/jimmunol.0900722
  26. Bochud, 2007, Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection, J Infect Dis, 196, 505, 10.1086/519693 · DOI
  27. Zhang, 2007, TLR3 deficiency in patients with herpes simplex encephalitis, Science, 317, 1522, 10.1126/science.1139522 · DOI · Paper page
  28. Akira, 2004, Toll-like receptor signalling, Nat Rev Immunol, 4, 499, 10.1038/nri1391 · DOI · Paper page
  29. Fish, 1983, Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells, Biochem Biophys Res Commun, 112, 537, 10.1016/0006-291X(83)91498-5 · doi:10.1016/0006-291x(83)91498-5
  30. Leventon-Kriss, 1987, Sensitivity in vitro of herpes simplex virus isolates to human fibroblast interferon, Med Microbiol Immunol, 176, 151, 10.1007/BF00193896 · doi:10.1007/bf00193896
  31. Nazli, 2009, Differential induction of innate anti-viral responses by TLR ligands against Herpes simplex virus, type 2, infection in primary genital epithelium of women, Antivir Res, 81, 103, 10.1016/j.antiviral.2008.10.005 · DOI
  32. Gill, 2011, NK cells require type I IFN receptor for antiviral responses during genital HSV-2 infection, Cell Immunol, 269, 29, 10.1016/j.cellimm.2011.03.007 · DOI
  33. Conrady, 2011, Loss of the type I interferon pathway increases vulnerability of mice to genital herpes simplex virus 2 infection, J Virol, 85, 1625, 10.1128/JVI.01715-10 · DOI
  34. Peng, 2009, Evasion of the mucosal innate immune system by herpes simplex virus type 2, J Virol, 83, 12559, 10.1128/JVI.00939-09 · DOI
  35. Vivier, 2008, Functions of natural killer cells, Nat Immunol, 9, 503, 10.1038/ni1582 · DOI · Paper page
  36. Bogdan, 2001, Nitric oxide and the immune response, Nat Immunol, 2, 907, 10.1038/ni1001-907 · DOI · Paper page
  37. Ashkar, 2003, Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection, J Virol, 77, 10168, 10.1128/JVI.77.18.10168-10171.2003 · DOI · Paper page
  38. Cunningham, 1985, Evolution of recurrent herpes simplex lesions. An immunohistologic study, J Clin Invest, 75, 226, 10.1172/JCI111678 · DOI · Paper page
  39. Koelle, 1998, Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes, J Clin Invest, 101, 1500, 10.1172/JCI1758 · DOI · Paper page
  40. Bjorkstrom, 2011, Characterization of natural killer cell phenotype and function during recurrent human HSV-2 infection, PLoS One, 6, e27664, 10.1371/journal.pone.0027664 · DOI
  41. Donaghy, 2009, Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection, J Virol, 83, 1952, 10.1128/JVI.01578-08 · DOI
  42. Siegal, 1981, Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions, N Engl J Med, 305, 1439, 10.1056/NEJM198112103052403 · DOI · Paper page
  43. Naraqi, 1977, Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts, J Infect Dis, 136, 531, 10.1093/infdis/136.4.531 · doi:10.1093/infdis/136.4.531
  44. Meyers, 1980, Infection with herpes simplex virus and cell-mediated immunity after marrow transplant, J Infect Dis, 142, 338, 10.1093/infdis/142.3.338 · DOI · Paper page
  45. Morrison, 2008, Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells, Virology, 376, 205, 10.1016/j.virol.2008.03.010 · DOI
  46. Iijima, 2008, Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus, J Exp Med, 205, 3041, 10.1084/jem.20082039 · DOI
  47. Schiffer, 2010, Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes, Proc Natl Acad Sci U S A, 107, 18973, 10.1073/pnas.1006614107 · DOI
  48. Mbopi-Keou, 2003, Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2, Clin Diagn Lab Immunol, 10, 388, 10.1128/CDLI.10.3.388-393.2003 · doi:10.1128/cdli.10.3.388-393.2003
  49. Cappel, 1985, Clinical efficacy of a herpes simplex subunit vaccine, J Med Virol, 16, 137, 10.1002/jmv.1890160206 · DOI
  50. Mertz, 1990, Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection, J Infect Dis, 161, 653, 10.1093/infdis/161.4.653 · DOI
  51. Ashley, 1985, Humoral immune response to herpes simplex virus type 2 glycoproteins in patients receiving a glycoprotein subunit vaccine, J Virol, 56, 475, 10.1128/JVI.56.2.475-481.1985 · DOI
  52. Mester, 1990, Herpes simplex virus type 1-specific immunity induced by peptides corresponding to an antigenic site of glycoprotein B, J Virol, 64, 5277, 10.1128/JVI.64.11.5277-5283.1990 · DOI
  53. Straus, 1994, Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes, Lancet, 343, 1460, 10.1016/S0140-6736(94)92581-X · DOI · Paper page
  54. Corey, 1999, Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV vaccine study group, JAMA, 282, 331, 10.1001/jama.282.4.331 · DOI · Paper page
  55. Langenberg, 1999, A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV vaccine study group, N Engl J Med, 341, 1432, 10.1056/NEJM199911043411904 · DOI · Paper page
  56. Bernstein, 2005, Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine, Clin Infect Dis, 40, 1271, 10.1086/429240 · doi:10.1086/429240
  57. Stanberry, 2002, Glycoprotein-D-adjuvant vaccine to prevent genital herpes, N Engl J Med, 347, 1652, 10.1056/NEJMoa011915 · DOI · Paper page
  58. Immunology, 2010, Painful failure of promising genital herpes vaccine, Science, 330, 304, 10.1126/science.330.6002.304 · doi:10.1126/science.330.6002.304
  59. Straus, 1997, Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial, J Infect Dis, 176, 1129, 10.1086/514103 · DOI · Paper page
  60. Koelle, 2008, Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naive and HSV-2-infected subjects, Clin Vaccine Immunol, 15, 773, 10.1128/CVI.00020-08 · DOI
  61. Wald, 2011, Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons, Vaccine, 29, 8520, 10.1016/j.vaccine.2011.09.046 · DOI
  62. Meignier, 1988, Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1, Virology, 162, 251, 10.1016/0042-6822(88)90417-5 · DOI · Paper page
  63. McLean, 1994, Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1, J Infect Dis, 170, 1100, 10.1093/infdis/170.5.1100 · DOI
  64. Boursnell, 1997, A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease, J Infect Dis, 175, 16, 10.1093/infdis/175.1.16 · DOI
  65. de Bruyn, 2006, A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects, Vaccine, 24, 914, 10.1016/j.vaccine.2005.08.088 · doi:10.1016/j.vaccine.2005.08.088
  66. Casanova, 2002, A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections, Cutis, 70, 235
  67. Shedlock, 2000, DNA vaccination: antigen presentation and the induction of immunity, J Leukoc Biol, 68, 793, 10.1189/jlb.68.6.793 · DOI · Paper page
  68. Cattamanchi, 2008, Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system, Clin Vaccine Immunol, 15, 1638, 10.1128/CVI.00167-08 · DOI
  69. Brans, 2010, Immunization with a dominant-negative recombinant herpes simplex virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs, BMC Microbiol, 10, 163, 10.1186/1471-2180-10-163 · DOI
  70. Suter, 1999, BAC-VAC, a novel generation of (DNA) vaccines: a bacterial artificial chromosome (BAC) containing a replication-competent, packaging-defective virus genome induces protective immunity against herpes simplex virus 1, Proc Natl Acad Sci U S A, 96, 12697, 10.1073/pnas.96.22.12697 · DOI
  71. Zhang, 2009, A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge, Mucosal Immunol, 2, 129, 10.1038/mi.2008.81 · DOI · Paper page
  72. Armerding, 1981, In-vivo modulation of macrophage functions by herpes simplex virus type 2 in resistant and sensitive inbred mouse strains, Immunobiology, 160, 217, 10.1016/S0171-2985(81)80049-6 · doi:10.1016/s0171-2985(81)80049-6
  73. Scriba, 1981, Persistence of herpes simplex virus (HSV) infection in ganglia and peripheral tissues of guinea pigs, Med Microbiol Immunol, 169, 91, 10.1007/BF02171776 · doi:10.1007/bf02171776
  74. Scriba, 1981, Pathogenesis of herpes simplex virus infections in guinea pigs, Infect Immun, 34, 655, 10.1128/IAI.34.3.655-661.1981 · doi:10.1128/iai.34.3.655-661.1981
  75. Bourne, 1994, Quantity of latency-associated transcript produced by herpes simplex virus is not predictive of the frequency of experimental recurrent genital herpes, J Infect Dis, 169, 1084, 10.1093/infdis/169.5.1084 · doi:10.1093/infdis/169.5.1084
  76. Dudek, 2006, Replication-defective viruses as vaccines and vaccine vectors, Virology, 344, 230, 10.1016/j.virol.2005.09.020 · DOI · Paper page
  77. Dudek, 2011, Evidence for differences in immunologic and pathogenesis properties of herpes simplex virus 2 strains from the United States and South Africa, J Infect Dis, 203, 1434, 10.1093/infdis/jir047 · doi:10.1093/infdis/jir047
  78. Krause, 1995, Expression of the herpes simplex virus type 2 latency-associated transcript enhances spontaneous reactivation of genital herpes in latently infected guinea pigs, J Exp Med, 181, 297, 10.1084/jem.181.1.297 · DOI
  79. Bernstein, 2001, Potential for immunotherapy in the treatment of herpesvirus infections, Herpes, 8, 8
  80. Da Costa, 1997, Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease, Virology, 232, 1, 10.1006/viro.1997.8564 · DOI
  81. Hoshino, 2005, Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs, J Virol, 79, 410, 10.1128/JVI.79.1.410-418.2005 · DOI
  82. Hoshino, 2009, Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs, J Infect Dis, 200, 1088, 10.1086/605645 · DOI
  83. Hoshino, 2008, Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs, Vaccine, 26, 4034, 10.1016/j.vaccine.2008.05.022 · doi:10.1016/j.vaccine.2008.05.022
  84. McLean, 1996, Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine, Vaccine, 14, 987, 10.1016/0264-410X(95)00259-4 · DOI
  85. Meignier, 1988, In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents, J Infect Dis, 158, 602, 10.1093/infdis/158.3.602 · DOI · Paper page
  86. Prichard, 2005, Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs, Vaccine, 23, 5424, 10.1016/j.vaccine.2005.02.028 · DOI
  87. Spector, 1998, Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs, J Infect Dis, 177, 1143, 10.1086/515278 · DOI
  88. Wachsman, 2001, A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs, Vaccine, 19, 1879, 10.1016/S0264-410X(00)00446-1 · DOI
  89. Bernstein, 2000, Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection, Vaccine, 18, 1351, 10.1016/S0264-410X(99)00416-8 · DOI
  90. Bernstein, 2011, Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig, Vaccine, 29, 2071, 10.1016/j.vaccine.2011.01.005 · doi:10.1016/j.vaccine.2011.01.005
  91. Bernstein, 2010, The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs, Vaccine, 28, 3748, 10.1016/j.vaccine.2009.10.025 · doi:10.1016/j.vaccine.2009.10.025
  92. Bourne, 2003, Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs, J Infect Dis, 187, 542, 10.1086/374002 · doi:10.1086/374002
  93. Bourne, 2005, Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected, J Infect Dis, 192, 2117, 10.1086/498247 · DOI
  94. Bourne, 1996, DNA immunization against experimental genital herpes simplex virus infection, J Infect Dis, 173, 800, 10.1093/infdis/173.4.800 · DOI
  95. Fotouhi, 2008, Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting, FEMS Immunol Med Microbiol, 54, 18, 10.1111/j.1574-695X.2008.00438.x · doi:10.1111/j.1574-695x.2008.00438.x
  96. Heineman, 1995, Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs, J Virol, 69, 8109, 10.1128/JVI.69.12.8109-8113.1995 · doi:10.1128/jvi.69.12.8109-8113.1995
  97. McClements, 1997, The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs, Vaccine, 15, 857, 10.1016/S0264-410X(96)00246-0 · doi:10.1016/s0264-410x(96)00246-0
  98. Mester, 1999, Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C, Vaccine, 18, 875, 10.1016/S0264-410X(99)00325-4 · doi:10.1016/s0264-410x(99)00325-4
  99. Morello, 2011, Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease, J Virol, 85, 3461, 10.1128/JVI.02521-10 · DOI
  100. Natuk, 2006, Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge, J Virol, 80, 4447, 10.1128/JVI.80.9.4447-4457.2006 · doi:10.1128/jvi.80.9.4447-4457.2006
  101. O'Hagan, 1999, Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs, Vaccine, 17, 2229, 10.1016/S0264-410X(99)00009-2 · DOI
  102. Quenelle, 2006, Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2, Vaccine, 24, 1515, 10.1016/j.vaccine.2005.10.017 · DOI
  103. Scriba, 1976, Recurrent genital herwpes simplex virus (HSV) infection of guinea pigs, Med Microbiol Immunol, 162, 201, 10.1007/BF02120998 · doi:10.1007/bf02120998
  104. Yim, 2005, The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies, J Virol, 79, 14632, 10.1128/JVI.79.23.14632-14639.2005 · DOI
  105. McDermott, 1984, Immunity in the female genital tract after intravaginal vaccination of mice with an attenuated strain of herpes simplex virus type 2, J Virol, 51, 747, 10.1128/JVI.51.3.747-753.1984 · doi:10.1128/jvi.51.3.747-753.1984
  106. Parr, 1994, A mouse model for studies of mucosal immunity to vaginal infection by herpes simplex virus type 2, Lab Invest, 70, 369
  107. Smith, 2002, Pathogenesis of herpes simplex virus type 2 virion host shutoff (vhs) mutants, J Virol, 76, 2054, 10.1128/jvi.76.5.2054-2061.2002 · doi:10.1128/jvi.76.5.2054-2061.2002
  108. Luo, 2012, Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2, Front Microbiol, 3, 158, 10.3389/fmicb.2012.00158 · doi:10.3389/fmicb.2012.00158
  109. Lee, 2002, Immunization with combined HSV-2 glycoproteins B2: D2 gene DNAs: protection against lethal intravaginal challenges in mice, Virus Genes, 25, 179, 10.1023/A:1020113902834 · doi:10.1023/a:1020113902834
  110. Beutler, 2003, How we detect microbes and respond to them: the Toll-like receptors and their transducers, J Leukoc Biol, 74, 479, 10.1189/jlb.0203082 · DOI · Paper page
  111. Gill, 2006, Induction of innate immunity against herpes simplex virus type 2 infection via local delivery of Toll-like receptor ligands correlates with beta interferon production, J Virol, 80, 9943, 10.1128/JVI.01036-06 · DOI
  112. Ashkar, 2004, Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA, J Infect Dis, 190, 1841, 10.1086/425079 · DOI
  113. Svensson, 2007, Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection, J Reprod Immunol, 74, 114, 10.1016/j.jri.2006.09.002 · DOI
  114. Swann, 2007, Type I IFN contributes to NK cell homeostasis, activation, and antitumor function, J Immunol, 178, 7540, 10.4049/jimmunol.178.12.7540 · DOI · Paper page
  115. Martinez, 2008, Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo, J Immunol, 180, 1592, 10.4049/jimmunol.180.3.1592 · DOI · Paper page
  116. Milligan, 1997, Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract, Virology, 229, 259, 10.1006/viro.1997.8441 · DOI · Paper page
  117. Gill, 2009, Overexpression of interleukin-15 compromises CD4-dependent adaptive immune responses against herpes simplex virus 2, J Virol, 83, 918, 10.1128/JVI.01282-08 · doi:10.1128/jvi.01282-08
  118. Parr, 2003, Vaginal immunity in the HSV-2 mouse model, Int Rev Immunol, 22, 43, 10.1080/08830180305228 · doi:10.1080/08830180305228
  119. Parr, 1998, Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice, Immunology, 95, 208, 10.1046/j.1365-2567.1998.00587.x · doi:10.1046/j.1365-2567.1998.00587.x
  120. Parr, 1997, Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2, J Virol, 71, 8109, 10.1128/JVI.71.11.8109-8115.1997 · doi:10.1128/jvi.71.11.8109-8115.1997
  121. Russell, 2002, Humoral immune responses to microbial infections in the genital tract, Microbe Infect, 4, 667, 10.1016/S1286-4579(02)01585-X · DOI
  122. Harandi, 2001, Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice, J Gen Virol, 82, 845, 10.1099/0022-1317-82-4-845 · DOI
  123. Kuklin, 1998, Role of mucosal immunity in herpes simplex virus infection, J Immunol, 160, 5998, 10.4049/jimmunol.160.12.5998 · DOI
  124. Milligan, 1998, T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2, J Immunol, 160, 6093, 10.4049/jimmunol.160.12.6093 · DOI · Paper page
  125. McDermott, 1989, T lymphocytes in genital lymph nodes protect mice from intravaginal infection with herpes simplex virus type 2, J Infect Dis, 159, 460, 10.1093/infdis/159.3.460 · doi:10.1093/infdis/159.3.460
  126. Brabin, 2002, Interactions of the female hormonal environment, susceptibility to viral infections, and disease progression, AIDS Patient Care STDS, 16, 211, 10.1089/10872910252972267 · DOI
  127. Kaushic, 2011, Increased prevalence of sexually transmitted viral infections in women: the role of female sex hormones in regulating susceptibility and immune responses, J Reprod Immunol, 10.1016/j.jri.2010.12.004 · DOI
  128. Kaushic, 2003, Progesterone increases susceptibility and decreases immune responses to genital herpes infection, J Virol, 77, 4558, 10.1128/JVI.77.8.4558-4565.2003 · DOI · Paper page
  129. Gillgrass, 2003, Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2, J Virol, 77, 9845, 10.1128/JVI.77.18.9845-9851.2003 · DOI
  130. Gillgrass, 2005, Estradiol regulates susceptibility following primary exposure to genital herpes simplex virus type 2, while progesterone induces inflammation, J Virol, 79, 3107, 10.1128/JVI.79.5.3107-3116.2005 · DOI
  131. Gillgrass, 2005, Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue, J Virol, 79, 3117, 10.1128/JVI.79.5.3117-3126.2005 · DOI
  132. Bhavanam, 2008, Intranasal and subcutaneous immunization under the effect of estradiol leads to better protection against genital HSV-2 challenge compared to progesterone, Vaccine, 26, 6165, 10.1016/j.vaccine.2008.08.045 · doi:10.1016/j.vaccine.2008.08.045
  133. Pennock, 2009, Estradiol improves genital herpes vaccine efficacy in mice, Vaccine, 10.1016/j.vaccine.2009.07.052 · doi:10.1016/j.vaccine.2009.07.052
  134. Roth, 2012, Delayed but effective induction of mucosal memory immune responses against genital HSV-2 in the absence of secondary lymphoid organs, Mucosal Immunol
  135. Kwant, 2004, Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2, Vaccine, 22, 3098, 10.1016/j.vaccine.2004.01.059 · DOI
  136. Tengvall, 2005, CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice, J Reprod Immunol, 68, 53, 10.1016/j.jri.2005.06.010 · DOI
  137. Awasthi, 2011, J Virol, 85, 10472, 10.1128/JVI.00849-11 · DOI
  138. Parr, 1998, Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2, J Virol, 72, 5137, 10.1128/JVI.72.6.5137-5145.1998 · DOI
  139. Del Campo, 2010, Intranasal immunization with a proteoliposome-derived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice, Vaccine, 28, 1193, 10.1016/j.vaccine.2009.11.035 · DOI
  140. Gallichan, 1998, Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization, J Infect Dis, 177, 1155, 10.1086/515286 · DOI
  141. Gallichan, 2001, Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract, J Immunol, 166, 3451, 10.4049/jimmunol.166.5.3451 · DOI · Paper page
  142. Milligan, 2004, Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa, Virology, 318, 507, 10.1016/j.virol.2003.10.010 · DOI
  143. Parr, 1999, Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2, Immunology, 98, 639, 10.1046/j.1365-2567.1999.00909.x · doi:10.1046/j.1365-2567.1999.00909.x
  144. Morrison, 1998, Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge, Virology, 243, 178, 10.1006/viro.1998.9047 · DOI

Metadata

Authors
Roth, K., Ferreira, V. H., & Kaushic, C.
Venue
Microbial Pathogenesis
Publisher
Elsevier BV
Published
2013-05
Volume
58
Pages
45-54
ISSN
0882-4010
Cited by
35
References
1
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HSV-2 vaccine: Current state and insights into development of a vaccine that targets genital mucosal protection. https://app.cochat.ai/papers/10.1016/j.micpath.2012.11.001
The paper
Roth, K., Ferreira, V. H., & Kaushic, C. (2013). HSV-2 vaccine: Current state and insights into development of a vaccine that targets genital mucosal protection. Microbial Pathogenesis. https://doi.org/10.1016/j.micpath.2012.11.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.